Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242.
Fiche du document
2012
- doi: 10.1016/j.virol.2011.11.008
- issn: 0042-6822
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.virol.2011.11.008
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/22154237
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1096-0341
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_25C08A458D939
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Arenaviridae ArenovirusesCiter ce document
A. Pasquato et al., « Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242. », Serveur académique Lausannois, ID : 10.1016/j.virol.2011.11.008
Métriques
Partage / Export
Résumé
The cellular protease subtilisin kexin isozyme-1 (SKI-1)/site-1 protease (S1P) is implicated in the proteolytic processing of the viral envelope glycoprotein precursor (GPC) of arenaviruses, a step strictly required for production of infectious progeny. The small molecule SKI-1/S1P inhibitor PF-429242 was shown to have anti-viral activity against Old World arenaviruses. Here we extended these studies and show that PF-429242 also inhibits GPC processing and productive infection of New World arenaviruses, making PF-429242 a broadly active anti-arenaviral drug. In combination therapy, PF-429242 potentiated the anti-viral activity of ribavirin, indicating a synergism between the two drugs. A hallmark of arenaviruses is their ability to establish persistent infection in vitro and in vivo. Notably, PF-429242 was able to efficiently and rapidly clear persistent infection by arenaviruses. Interruption of drug treatment did not result in re-emergence of infection, indicating that PF-429242 treatment leads to virus extinction.